Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma
THURSDAY, June 10, 2021 -- For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | Pharmaceuticals | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants